Form 4 for MREO Mereo BioPharma Group plc
Accepted 2024-09-13 00:00:00 ET · period of report 2024-09-11 · accession 0000950170-24-106417 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-09-13 | 2024-09-11 | MREO | Scots-Knight Denise | CEO, Dir | M - OptEx | $0.00 | +188.1K | 897.6K | +27% | $0 |
| D | 2024-09-13 | 2024-09-11 | MREO | Scots-Knight Denise | CEO, Dir | M - OptEx | $0.00 | -188.1K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | American Depositary Shares representing Ordinary Shares | 2024-09-11 | M | A | 188,060 | $0.00 | 897,578 | D | — | — | (F3) Reporting Person also beneficially owns 4 ordinary shares, nominal value of GBP 0.003 per ordinary share, of the Issuer. (F1) Each American Depositary Share ("ADS") represents five ordinary shares, nominal value GBP 0.003 per ordinary share, of the Issuer. (F2) Represents performance-based restricted stock unit earned under the Issuer's 2019 Employee Incentive Plan (the "Plan"), that vested on September 11, 2024 based on satisfaction of ADS price threshold values over a two year performance period. (F4) Includes 1,200 ADSs jointly owned by Reporting person and her spouse. |
| 2 | Derivative | Performance Based Restricted Stock Unit | 2024-09-11 | M | D | 188,060 | $0.00 | 0 | D | $0.00 · 2024-09-11 to 2025-01-25 | 188,060 American Depository Shares |